Br J Anaesth:外科术后入ICU患者的虚弱程度与临床结局之间的关系:一项系统综述和Meta分析

2022-02-16 贵州医科大学 麻醉与心脏电生理课题组 “罂粟花”公众号

背景:

背景:术前虚弱可能是术后不良结果的有力预测指标。我们调查了外科术后入ICU患者的虚弱程度和临床结果之间的关系。

方法:我们检索了PubMed、Embase和Ovid MEDLINE数据库中收录的应用虚弱程度的相关文献原文。文献报导了术后入ICU成年(≥18岁)外科患者的结局,并以死亡率为主要观察指标。提取患者死亡率、机械通气时间、ICU和住院时间以及出院目的地的数据。纳入研究的质量和偏倚风险采用渥太华纽卡斯尔量表进行评估。根据系统综述和Meta分析指南的首选项目来综合处理数据。

结果:共有13项观察性研究符合纳入标准。总共纳入58757名患者,其中22793名(39.4%)存在身体虚弱状况。虚弱与短期风险(风险比:2.66;95%可信区间[CI]:1.99-3.56)和长期死亡率(风险比:2.66;95%CI:1.32-5.37)相关。虚弱患者的ICU住院天数(均差[MD]=1.5天;95%CI:0.8-2.2)和住院天数(MD=3.9天;95%CI:1.4-6.5)较长。虚弱患者的机械通气时间更长(MD=22h;95%CI:1.7-42.3),而虚弱患者出院后也更大概率转运到医疗机构继续治疗(RR=2.34;95%CI:1.36-4.01)。

结论:因择期手术或急诊手术而需要术后入ICU的虚弱患者的死亡风险增加,住院时间延长,非家庭出院的可能性增加。术前虚弱评估和风险分层在患者与临床医生的计划,以及重症监护资源的利用中是必不可少的。

原始出处:

Rachel Chan, Ryo Ueno, Afsana Afroz, et al. Association between frailty and clinical outcomes in surgical patients admitted to intensive care units: a systematic review and meta-analysis. [J]Br J Anaesth, 128(2): 258-271(2022).

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1896979, encodeId=4a5618969e931, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Sep 26 07:33:11 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633624, encodeId=d42816336246f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed May 11 11:33:11 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888409, encodeId=e204188840907, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 22:33:11 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971861, encodeId=56dd19e186193, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Apr 30 18:33:11 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051754, encodeId=c26e2051e549a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Mar 12 08:33:11 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843282, encodeId=20d418432828f, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Oct 15 13:33:11 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197312, encodeId=59cb119e31297, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:28 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595394, encodeId=87b91595394d1, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 18 05:33:11 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194207, encodeId=fb39119420e35, content=有<a href='/topic/show?id=9c8b104458f6' target=_blank style='color:#2F92EE;'>#虚弱量表#</a>可以用, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104458, encryptionId=9c8b104458f6, topicName=虚弱量表)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:42:10 CST 2022, time=2022-02-16, status=1, ipAttribution=)]
    2022-09-26 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1896979, encodeId=4a5618969e931, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Sep 26 07:33:11 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633624, encodeId=d42816336246f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed May 11 11:33:11 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888409, encodeId=e204188840907, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 22:33:11 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971861, encodeId=56dd19e186193, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Apr 30 18:33:11 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051754, encodeId=c26e2051e549a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Mar 12 08:33:11 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843282, encodeId=20d418432828f, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Oct 15 13:33:11 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197312, encodeId=59cb119e31297, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:28 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595394, encodeId=87b91595394d1, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 18 05:33:11 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194207, encodeId=fb39119420e35, content=有<a href='/topic/show?id=9c8b104458f6' target=_blank style='color:#2F92EE;'>#虚弱量表#</a>可以用, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104458, encryptionId=9c8b104458f6, topicName=虚弱量表)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:42:10 CST 2022, time=2022-02-16, status=1, ipAttribution=)]
    2022-05-11 AspirantSuo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1896979, encodeId=4a5618969e931, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Sep 26 07:33:11 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633624, encodeId=d42816336246f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed May 11 11:33:11 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888409, encodeId=e204188840907, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 22:33:11 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971861, encodeId=56dd19e186193, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Apr 30 18:33:11 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051754, encodeId=c26e2051e549a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Mar 12 08:33:11 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843282, encodeId=20d418432828f, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Oct 15 13:33:11 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197312, encodeId=59cb119e31297, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:28 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595394, encodeId=87b91595394d1, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 18 05:33:11 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194207, encodeId=fb39119420e35, content=有<a href='/topic/show?id=9c8b104458f6' target=_blank style='color:#2F92EE;'>#虚弱量表#</a>可以用, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104458, encryptionId=9c8b104458f6, topicName=虚弱量表)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:42:10 CST 2022, time=2022-02-16, status=1, ipAttribution=)]
    2022-08-08 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1896979, encodeId=4a5618969e931, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Sep 26 07:33:11 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633624, encodeId=d42816336246f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed May 11 11:33:11 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888409, encodeId=e204188840907, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 22:33:11 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971861, encodeId=56dd19e186193, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Apr 30 18:33:11 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051754, encodeId=c26e2051e549a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Mar 12 08:33:11 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843282, encodeId=20d418432828f, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Oct 15 13:33:11 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197312, encodeId=59cb119e31297, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:28 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595394, encodeId=87b91595394d1, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 18 05:33:11 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194207, encodeId=fb39119420e35, content=有<a href='/topic/show?id=9c8b104458f6' target=_blank style='color:#2F92EE;'>#虚弱量表#</a>可以用, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104458, encryptionId=9c8b104458f6, topicName=虚弱量表)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:42:10 CST 2022, time=2022-02-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1896979, encodeId=4a5618969e931, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Sep 26 07:33:11 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633624, encodeId=d42816336246f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed May 11 11:33:11 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888409, encodeId=e204188840907, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 22:33:11 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971861, encodeId=56dd19e186193, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Apr 30 18:33:11 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051754, encodeId=c26e2051e549a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Mar 12 08:33:11 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843282, encodeId=20d418432828f, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Oct 15 13:33:11 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197312, encodeId=59cb119e31297, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:28 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595394, encodeId=87b91595394d1, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 18 05:33:11 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194207, encodeId=fb39119420e35, content=有<a href='/topic/show?id=9c8b104458f6' target=_blank style='color:#2F92EE;'>#虚弱量表#</a>可以用, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104458, encryptionId=9c8b104458f6, topicName=虚弱量表)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:42:10 CST 2022, time=2022-02-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1896979, encodeId=4a5618969e931, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Sep 26 07:33:11 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633624, encodeId=d42816336246f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed May 11 11:33:11 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888409, encodeId=e204188840907, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 22:33:11 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971861, encodeId=56dd19e186193, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Apr 30 18:33:11 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051754, encodeId=c26e2051e549a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Mar 12 08:33:11 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843282, encodeId=20d418432828f, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Oct 15 13:33:11 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197312, encodeId=59cb119e31297, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:28 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595394, encodeId=87b91595394d1, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 18 05:33:11 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194207, encodeId=fb39119420e35, content=有<a href='/topic/show?id=9c8b104458f6' target=_blank style='color:#2F92EE;'>#虚弱量表#</a>可以用, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104458, encryptionId=9c8b104458f6, topicName=虚弱量表)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:42:10 CST 2022, time=2022-02-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1896979, encodeId=4a5618969e931, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Sep 26 07:33:11 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633624, encodeId=d42816336246f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed May 11 11:33:11 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888409, encodeId=e204188840907, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 22:33:11 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971861, encodeId=56dd19e186193, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Apr 30 18:33:11 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051754, encodeId=c26e2051e549a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Mar 12 08:33:11 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843282, encodeId=20d418432828f, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Oct 15 13:33:11 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197312, encodeId=59cb119e31297, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:28 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595394, encodeId=87b91595394d1, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 18 05:33:11 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194207, encodeId=fb39119420e35, content=有<a href='/topic/show?id=9c8b104458f6' target=_blank style='color:#2F92EE;'>#虚弱量表#</a>可以用, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104458, encryptionId=9c8b104458f6, topicName=虚弱量表)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:42:10 CST 2022, time=2022-02-16, status=1, ipAttribution=)]
    2022-02-25 ms4000001880486183

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1896979, encodeId=4a5618969e931, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Sep 26 07:33:11 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633624, encodeId=d42816336246f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed May 11 11:33:11 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888409, encodeId=e204188840907, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 22:33:11 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971861, encodeId=56dd19e186193, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Apr 30 18:33:11 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051754, encodeId=c26e2051e549a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Mar 12 08:33:11 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843282, encodeId=20d418432828f, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Oct 15 13:33:11 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197312, encodeId=59cb119e31297, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:28 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595394, encodeId=87b91595394d1, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 18 05:33:11 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194207, encodeId=fb39119420e35, content=有<a href='/topic/show?id=9c8b104458f6' target=_blank style='color:#2F92EE;'>#虚弱量表#</a>可以用, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104458, encryptionId=9c8b104458f6, topicName=虚弱量表)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:42:10 CST 2022, time=2022-02-16, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1896979, encodeId=4a5618969e931, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Sep 26 07:33:11 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633624, encodeId=d42816336246f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed May 11 11:33:11 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888409, encodeId=e204188840907, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Aug 08 22:33:11 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971861, encodeId=56dd19e186193, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Apr 30 18:33:11 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051754, encodeId=c26e2051e549a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Mar 12 08:33:11 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843282, encodeId=20d418432828f, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Oct 15 13:33:11 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197312, encodeId=59cb119e31297, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:28 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595394, encodeId=87b91595394d1, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 18 05:33:11 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194207, encodeId=fb39119420e35, content=有<a href='/topic/show?id=9c8b104458f6' target=_blank style='color:#2F92EE;'>#虚弱量表#</a>可以用, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104458, encryptionId=9c8b104458f6, topicName=虚弱量表)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:42:10 CST 2022, time=2022-02-16, status=1, ipAttribution=)]
    2022-02-16 医者仁者

    #虚弱量表#可以用

    0

相关资讯

J Endod:大块菌斑团块导致额外的根外感染和术后根尖周炎:一项病例汇报

这篇文章描述的是一例术后一直存在较严重根尖周炎的2颗上颌切牙通过根尖外科手术成功处理的病例。

JAHA:商业引入经导管二尖瓣修复术对二尖瓣外科手术的影响

商业引入TMVr与心脏手术的发展相关,并不会取消其他疗法,并且对所有接受治疗的二尖瓣返流患者都有良好的临床效果。

Anesth Analg:镁对外科手术患者寒战的预防作用:系统回顾与Meta分析

目前围术期镁的使用对寒战作用的临床试验结果不一,故本研究对围手术期镁预防寒战的效果进行了系统回顾和Meta分析。

Lancet:外科手术后为什么变傻了?

非-心脏外科手术能够提高生活质量和延长寿命,但是它也会带来一些并发症。美国外科学会国家外科质量改进项目发现在35万例进行低风险非-心脏外科手术(不包括大血管外科手术和神经外科手术)的患者中,485例(0.14%)发生了围手术期明显卒中(overt stroke,比如临床症状>24h的急性脑梗死)。一项国际随机试验纳入了8351例所有类型住院非-心脏外科手术的成人患者,60例(0.7%)发生了

2018 国际共识声明:外科手术后贫血的管理

尽管有许多管理手术患者贫血的指南,但在术后贫血和缺铁诊断和治疗方面确没有实用的指导指南。本文主要针对外科手术后贫血的管理提出建议声明,涉及手术患者铁缺乏和贫血的诊断,适合治疗患者的识别,以及实际管理和随访建议。

CCI可作为老年胃癌患者非治愈性ESD治疗后追加外科手术决策的有用参数

近几十年来,世界范围内老年人口规模迅速增长。胃癌在日本仍然是常见的死亡原因。内镜黏膜下剥离术(ESD)是一种公认的早期胃癌(EGC)的标准治疗方法。ESD被认为是一种侵入性较小的治疗方法,与开放手术相比,可改善术后生活质量。此外,许多研究显示ESD对EGC的短期和长期疗效良好,甚至对老年患者也是如此。